Colchicine in Patients with Chronic Coronary Disease.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Aug 2020 – Oct 2025Where it's discussed
-
X / Twitter209 posts
-
News147 articles
-
Facebook10 posts
-
Blogs9 articles
-
YouTube3 videos
AI synopsis
What people are saying
Several discussions highlight specific outcomes, such as the significant reduction in cardiovascular events (HR 0.69) observed in patients taking colchicine. Users frequently reference the details of the trial, mentioning the increased risk of non-cardiovascular mortality as a notable point of concern. Terms like 'game changer' and references to new treatment guidelines indicate a tone of both excitement and caution, as participants weigh the benefits against potential risks, contributing to the overall positive sentiment regarding the study's impact on future clinical practice.
Many discussions express supportive views about the effectiveness of colchicine in reducing cardiovascular events, indicating a general consensus on its application in clinical settings.
Participants show a high level of interest in the findings of the study, evidenced by numerous comments and explorations of its implications for treatment.
Posts reflect deep engagement, with users discussing research methodologies, citing specific trials, and considering the broader clinical context of the findings.
The publication is perceived as having a significant impact on treatment guidelines and clinical practices regarding chronic coronary disease.
Abstract in brief
- Recent trial results indicate that colchicine can significantly lower cardiovascular event risks in patients with chronic coronary disease.
- A total of 5522 patients were involved, with 2762 receiving colchicine and 2760 receiving a placebo, during an average follow-up of 28.6 months.
- Colchicine reduced the occurrence of primary and key secondary cardiovascular events compared to placebo, but there was a noted increase in non-cardiovascular mortality in the colchicine group.
Top posts
Most liked on X and Blueskyhttps://t.co/bxlHDHsXr4 https://t.co/prJt6BGESy
心血管イベント予防目的のコルヒチン0.5mg/day投与をFDAが許可 https://t.co/SItNZvNe6A 2020NEJMのRCT:心血管イベントを有意に低下 ・コルヒチン→ 6.8% ・プラセボ → 9.6% ⇨HR 0.69(95%CI 0.57-0.83) https://t.co/oU7XZPICEy https://t.co/JkwA5Z96CB
La evidencia de un ensayo reciente ha demostrado que los efectos antiinflamatorios de la colchicina reducen el riesgo de eventos cardiovasculares en pacientes con infarto de miocardio reciente. N Engl J Med 2020; 383: 1838-1847 DOI: 10.1056 / NEJMoa2021372 https://t.co/T2RzuLupZk
Let's start a discussion about colchicine in CAD. We have some decent data showing improvement in outcomes for chronic and acute CAD (see: https://t.co/JllJuLdxJm, https://t.co/zE48m7YtCB). Has anyone adopted this into practice? Why or why not? #CardioTwitter #Cardiology
All mentions
Colchicine's Impact on Chronic Coronary Disease Outcomes
Recent trial results indicate that colchicine can significantly lower cardiovascular event risks in patients with chronic coronary disease. This video explores the findings from a study involving 5522 patients…
Impact of Colchicine on Cardiovascular Risk in Chronic Disease Patients
Recent trial results indicate that colchicine can significantly lower cardiovascular event risks in patients with chronic coronary disease. The video discusses these findings and their implications for personalized care.
Impact of Heart Failure Treatments and Colchicine on Cardiovascular Risks
This podcast discusses starting heart failure medications during hospitalization, along with insights on the Impella device. Recent data on colchicine's effectiveness in reducing cardiovascular events among chronic…
少々古いですが、NEJMから 慢性冠動脈疾患患者を対象とした無作為化試験で、コルヒチン 0.5 mg の 1 日 1 回の投与を受けた患者は、プラセボの投与を受けた患者よりも心血管イベントのリスクが有意に低かった https://t.co/MQ68ipnwgQ
@eH_Khal @Banitoto Three Rx studied, Positive results=Canakinumab Negative results=Methotrexate https://t.co/ygEUls5dLL Conflicting data=Colchicine https://t.co/hYVoiEqKMj Only colchicine approved for this purpose in high risk pts.
RT @CroakeyNews: Talking about colchicine administered for coronary disease - why not develop a new drug? #MM2024AdPha https://t.co/aUHD2…
RT @CroakeyNews: Talking about colchicine administered for coronary disease - why not develop a new drug? #MM2024AdPha https://t.co/aUHD2…
Talking about colchicine administered for coronary disease - why not develop a new drug? #MM2024AdPha https://t.co/aUHD2KaS1G
@fischman_david @crfheart No, what about LoDoCo2? https://t.co/p8EL9gHKLN
Colchicine in Patients with Chronic Coronary Disease | NEJM The incidence of death from noncardiovascular causes was higher in the colchicine group than in the placebo group… https://t.co/HPoq7bTyxn https://t.co/DQ4oDNCmpr
@DrTrentAllen @dr_shai @TheEMboardround There are a couple of decently powered clinical trials that demonstrate, at low dose, a reduction in MI in pts with CAD. I actually use quite a bit and it's usually well tolerated at the relevant dose. https://t.co/h5qtFz1eGX https://t.co/GtNPETKf55
Low-dose oral colchicine (0.5 mg/d) was tested in two phase 3 trials of patients with CAD and also showed meaningful reductions in CV risk COLCOT (post-MI): https://t.co/zQRmSuopcn LoDoCo2 (chronic CAD): https://t.co/lwIVM5yNGw https://t.co/NX53XKlZkN
@HarrySpoelstra https://t.co/0eNZOSzNoU https://t.co/HBd8i3vDzy
the risk of cardiovascular events was significantly lower among those who received 0.5 mg of colchicine once daily than among those who received placebo Colchicine in Patients with Chronic Coronary Disease (LoDoCo2 Trial)| NEJM https://t.co/vfSpeyhoVq
RT @KazBowen: このあたりの論文が根拠・3割ぐらいLow dose コルヒチンで動脈硬化絡みのMajor eventが減る https://t.co/YHFAayB4Fi
このあたりの論文が根拠・3割ぐらいLow dose コルヒチンで動脈硬化絡みのMajor eventが減る https://t.co/YHFAayB4Fi
RT @DoctorTro:
RT @DoctorTro:
RT @DoctorTro:
RT @DoctorTro:
https://t.co/o7z0mQqZcS 冠動脈疾患のある5522患者に対するコルヒチン vs placeboのdouble-blinded RCT. 28.6ヶ月追跡、心血管イベントがコルヒチン群で減少(HR 0.69)。ヒト心血管疾患における慢性炎症のcausal roleを示したstudy。 NEJM, 2020.
13.
@Ecoxx21 @walinjom https://t.co/fvvXxbyLqS
2023 AHA guidelines recommended (2B) the addition of low dose colchicine in patients with chronic coronary disease for secondary prevention and reduction of recurrent ASCVD events.
@Drlipid LoDoCo2 already demonstrates this directly https://t.co/K8s0KWZFGD https://t.co/bHj7Zjf65M
4/5 LoDoCo2 ⚖️ (Randomized, double-blind, placebo controlled trial)
@MichaelJBlaha
RT @andreagallardo: “An old drug for a new CV indication”. ✅ Low dose colchicine in patients with chronic coronary disease ⤵️ Cardiovascu…
RT @yajadev: Colchicine in Patients with Chronic Coronary Disease | NEJM LoDoCo Trial #MedTwitter https://t.co/nIRUK0x22B
Colchicine in Patients with Chronic Coronary Disease | NEJM LoDoCo Trial #MedTwitter https://t.co/nIRUK0x22B
RT @IlindelatorreMD: https://t.co/bxlHDHsXr4 https://t.co/prJt6BGESy
RT @IlindelatorreMD: https://t.co/bxlHDHsXr4 https://t.co/prJt6BGESy
RT @IlindelatorreMD: https://t.co/bxlHDHsXr4 https://t.co/prJt6BGESy
https://t.co/bxlHDHsXr4 https://t.co/prJt6BGESy
RT @rheum_showa: 心血管イベント予防目的のコルヒチン0.5mg/day投与をFDAが許可 https://t.co/SItNZvNe6A 2020NEJMのRCT:心血管イベントを有意に低下 ・コルヒチン→ 6.8% ・プラセボ → 9.6% ⇨HR 0.…
RT @rheum_showa: 心血管イベント予防目的のコルヒチン0.5mg/day投与をFDAが許可 https://t.co/SItNZvNe6A 2020NEJMのRCT:心血管イベントを有意に低下 ・コルヒチン→ 6.8% ・プラセボ → 9.6% ⇨HR 0.…
RT @rheum_showa: 心血管イベント予防目的のコルヒチン0.5mg/day投与をFDAが許可 https://t.co/SItNZvNe6A 2020NEJMのRCT:心血管イベントを有意に低下 ・コルヒチン→ 6.8% ・プラセボ → 9.6% ⇨HR 0.…
RT @rheum_showa: 心血管イベント予防目的のコルヒチン0.5mg/day投与をFDAが許可 https://t.co/SItNZvNe6A 2020NEJMのRCT:心血管イベントを有意に低下 ・コルヒチン→ 6.8% ・プラセボ → 9.6% ⇨HR 0.…
RT @rheum_showa: 心血管イベント予防目的のコルヒチン0.5mg/day投与をFDAが許可 https://t.co/SItNZvNe6A 2020NEJMのRCT:心血管イベントを有意に低下 ・コルヒチン→ 6.8% ・プラセボ → 9.6% ⇨HR 0.…
心血管イベント予防目的のコルヒチン0.5mg/day投与をFDAが許可 https://t.co/SItNZvNe6A 2020NEJMのRCT:心血管イベントを有意に低下 ・コルヒチン→ 6.8% ・プラセボ → 9.6% ⇨HR 0.69(95%CI 0.57-0.83) https://t.co/oU7XZPICEy https://t.co/JkwA5Z96CB
Anti inflammatory agent Colchicine in patients with chronic coronary disease "...risk of cardiovascular events was significantly lower" in those receiving the med: https://t.co/aQQ968D2ZW @NutritionMadeS3 @Drlipid @JohnKastelein @DrMichaelSagner @Lipoprotein @drpablocorral
5/5 Great reviews: https://t.co/Z4H3q4tnZv https://t.co/LFlRvYHnYC @CardioNerds @ACCinTouch @JAMACardio @cardio
RT @thePagerNews:
@GermanSalgado22 @osmarperse @gonzaeperez @drpablocorral @JoseJuanatey @jpcostabel @valentin_vioj Entiendo que básicamente está sustentado en los resultados del estudio LoDoCo 2 en pacientes con síndrome coronario crónico clínicamente estable al menos por 6 meses. https://t.co/clD9WgENDM
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/GcAuLor7YT
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/ppc13h7mwD
2/ Approval is based on LoDoCo2 trial. MACE (PEP): 0.69, 0.57-0.83 CV death: 0.80, 0.44-1.44 MI: 0.70, 0.53-0.93 Stroke: 0.66, 0.35-1.25 Cor. revasc: 0.75, 0.60-0.94 ACM: 1.21, 0.86-1.71 Non-CV death: 1.51, 0.99-2.31 https://t.co/X7Nl7ea9cm
In a study of ~5500 people w/ chronic coronary disease, colchicine reduced risk of heart attack, stroke, revascularization or death by ~30%, from 3.6 to 2.5 per 100 PY. It previously showed benefit for people who had already had a heart attack. 2/ https://t.co/BDIEf1IUFZ
... o revascularización coronaria por isquemia y muerte cardiovascular fueron significativamente más bajos en el grupo de #Colchicina. Además, la incidencia de muerte por otras causas fue mayor con Colchicina (0.7 vs. 0.5 eventos/100k personas—año). https://t.co/rYg7tGOd9x
RT @javier20ch:
RT @javier20ch:
RT @javier20ch:
RT @javier20ch:
RT @javier20ch:
RT @javier20ch:
RT @javier20ch:
RT @javier20ch:
turning severe C19 into asymptomatic C19, doesn't this STILL make a case for additional treatments after vaccination, especially with drugs which are already known to prevent heart issues?
12/ For a median follow-up of 28.6 months, colchicine reduced major cardiovascular outcomes (cardiovascular death, spontaneous MI, stroke, or coronary revascularization). https://t.co/x08gU8MQ4W
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/iHmKc97I4M
@kevinnbass Thoughts on continuing colchicine indefinitely? https://t.co/OSekkVawz0
Always coming to my mind after the Colchicine in Patients with Chronic Coronary Disease study in @NEJM .. Why it is not colchicine/dexa after acute pyelonephritis? Then i found this @Ped_Neph: https://t.co/dLXlfeL1Zp No effect of dexa on kidney scarring after acute PN
RT @accpcardprn: Let's start a discussion about colchicine in CAD. We have some decent data showing improvement in outcomes for chronic and…
Let's start a discussion about colchicine in CAD. We have some decent data showing improvement in outcomes for chronic and acute CAD (see: https://t.co/JllJuLdxJm, https://t.co/zE48m7YtCB). Has anyone adopted this into practice? Why or why not? #CardioTwitter #Cardiology
@davidasinclair @hubermanlab https://t.co/jP0pPt1LVh
@CatherineWangMD I’m definitely not a
RT @StellaMMacin: Benefit of colchicine independent of timing of prior ACS Colchicine in Patients With Chronic Coronary Disease in Relation…
Wetenschap in Noordwest: “Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome”: https://t.co/Ba0DaBIc1H @noordwestzh #wetenschapNoordwest #colchicine #AcuteCoronarySyndrome #samenbeter
Benefit of colchicine independent of timing of prior ACS Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome TSJ et al., JACC. 2021
RT @CardioNerdsJC: To get situated: check out the powerful
To get situated: check out the powerful
Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome https://t.co/am6sc1xa4P vía @practiceupdate
RT @Reumaclinic: An old friend in Rheumatology, cheap with low toxicity and benefits over cardiovascular outcomes https://t.co/L6xwyTNJg7…
#047 Colchicine in Patients with Chronic Coronary Disease N Engl J Med 2020;383:1838-47.
RT @PracUpCardio: Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome https://t.co/t2pWCnijUS…
Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome https://t.co/t2pWCnijUS #cardiology
RT @BebetoDice: @Mr_Jeffry @PhellixR Ojo , fallo en reducir el tamaño del infarto . Pero en enfermedad CV crónica redujo significativamente…
@Mr_Jeffry @PhellixR Ojo , fallo en reducir el tamaño del infarto . Pero en enfermedad CV crónica redujo significativamente los eventos coronarios https://t.co/aByPyW52Js
Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome - https://t.co/FpEFRPWYTi
Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome - https://t.co/tHpj4Zxz5E
Today's #journalclub, good sample size, appropriate design. Not reflecting our patient population. How control study group are in #BP, #LDL #DM #Weight Interaction of #statin and #colchicine? Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/9awwgFIlXG
https://t.co/Uvt42UErVA Do we have any guidelines on the base of this trial and how many cardiologist are giving their patients colchicine?? @American_Heart @JACCJournals
@Toluhwalase Yes! The 3 studies Farouk presented on are below: 1) Long term BB therapy & clinical outcomes after acute MI https://t.co/ZpMfDPwHKx 2) Early Rhythm Control in AF https://t.co/oBCsEksugx 3) Colchicine in Chronic CAD https://t.co/iEMta0IQi9
Colchicine in Patients with Chronic Coronary Disease | NEJM | #BotanicalMedicine https://t.co/JvkM4cNGX6
RT @CMichaelGibson: In a randomized trial of patients with chronic coronary disease, the risk of death, heart attack, stroke, or ischemia-d…
Study 10: 'Colchicine in Patients with Chronic Coronary Disease' by Stefan Nidorf et al. @NEJM pub date Nov 5 2020; https://t.co/bHEluLgEX4 Bottom line: 4 pts w/ stable CAD on evidence-based tx for 2ndary prevention, low-dose colchicine may further⬇️risk of cardiovascular events.
RT @WKSilverstein: We were then pleased to have @AmolAVerma present his top 5 GIM papers from 2020 (none on COVID!). They are linked below:…
We were then pleased to have @AmolAVerma present his top 5 GIM papers from 2020 (none on COVID!). They are linked below:https://t.co/wWZuJR89Mo; https://t.co/l2XeSjKQ2T; https://t.co/EICyLFScuo; https://t.co/HVv9ZrIjf5; https://t.co/LWoz0cij6J; https://t.co/NE1NEPCDEz
RT @MBE_SMUMFYC: Ayer tuvimos una entretenida y formativa sesión #clublectura #lecturacritica @smumfyc @commurcia del ECA Colchicine in Pa…
RT @MBE_SMUMFYC: Ayer tuvimos una entretenida y formativa sesión #clublectura #lecturacritica @smumfyc @commurcia del ECA Colchicine in Pa…
Colchicine in Patients with Chronic Coronary Disease | NEJM Cost efficient compared to #canakinumab https://t.co/gLOmuhRqyu https://t.co/XdcIzs9K9J
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/pzQU4ug4W0 Under enrollment of women and underreporting of sex-specific AEs https://t.co/60S59nGVjT
„In a randomized trial involving patients with chronic coronary disease, the risk of cardiovascular events was significantly lower among those who received 0.5 mg of colchicine once daily than among those who received placebo” | @NEJM https://t.co/f6dGwAqmHS
Will this change your practice? #colchicine #LoDoCo #CAD #MedTwitter https://t.co/ARW780yTM4
RT @MattiaGalli10: Check out our commentary to the LoDoCo2 trial. Colchicine has an antiplatelet effect that could explain both its effica…
Check out our commentary to the LoDoCo2 trial. Colchicine has an antiplatelet effect that could explain both its efficacy and the increased rate of non cardiovascular death. Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/mdfhfwxNen
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/8V9n3AVNRw
@filipe_rafaeli @entregacorisco @mab_sp125 @JoaoUchoa16 @Roth69808472 @LemesGiuliano Colchicina me parece crível aqui: https://t.co/s9TQiqBwYj
RT @ANCAM_MEXICO: Colchicina una vez al dia en sindrome coronario cronico, disminuye la muerte cardiovascular, infarto miocardio, evento va…
Colchicina una vez al dia en sindrome coronario cronico, disminuye la muerte cardiovascular, infarto miocardio, evento vascular cerebral o isquemia que lleva a revascularizacion, con HR 0.69 IC 0.57-0.83, p < 0.001. https://t.co/hnfq7sfJmY
RT @DrAiLynTan: #Colchicine reduces risk of #cardiovascular events in patients with #coronary disease ➡️31% lower relative risk of cardiov…
https://t.co/gPOZRxD9yW
Given that colchicine is effective in treating COVID-19, the following finding is a good recall indeed. Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/LKMJCOaCAB
Given that colchicine is effective in treating COVID-19, the following finding is a good recall indeed. Colchicine in Patients with Chronic Coronary Disease https://t.co/NTpPV3CVzf
@roi_cal A ver, entiendo tu preocupación,pero lo mismo lo mismo no es. La colchicina ha demostrado reducir mortalidad en cardiopatas... https://t.co/l0oMlrn4JD Y algo más de evidencia hay...
@PharmacistMama Here's the most recent study. Haven't seen much adoption on the front lines yet. https://t.co/zPGHho2INM
@Links_Medicus @ELS_Cardiology This was published by NEJM Nov 2020 https://t.co/vesKJgv7cv
Colchicine in Patients with Chronic Coronary Disease https://t.co/EBg2c7SVfp
6. RCT of 5522 with chronic coronary disease found a reduced risk of CV events with once daily colchicine compared with placebo https://t.co/FI7rnMIEca https://t.co/KnmftnDTB6
コルヒチンが安定狭心症での心血管死抑制する報告が出たと言うことで処方増えるのかな? https://t.co/6HNy5WHtvi
RT @MacDeptMed: ICYMI: Dr. John W Eikelboom, the LoDoCo2 Trial Investigators et al. assessed the effects of #colchicine in patients with ch…
ICYMI: Dr. John W Eikelboom, the LoDoCo2 Trial Investigators et al. assessed the effects of #colchicine in patients with chronic coronary disease. The risk of CV events was significantly lower among those who received 0.5 mg of colchicine once daily. #RCT https://t.co/6E8uJSBKTm https://t.co/ioLOfBDMkO
RT @AbeytuaManuel: Colchicine in Patients with Chronic Coronary Disease, the risk of cardiovascular events was significantly lower among th…
RT @RevistaMFSamfyc: Colchicina en pacientes con coronariopatía crónica https://t.co/YEX07P3GkB PMID 32865380
Colchicina en pacientes con coronariopatía crónica https://t.co/YEX07P3GkB PMID 32865380
RT @FarmaciaHums: Colchicina 0.5mg diarios disminuye riesgo de eventos cardiovasculares en pacientes con enfermedad coronaria crónica | NE…
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/eOS0Utet8Y
RT @mencardio: Colchicine in Patients With Chronic Coronary Disease | comment: Peter Libby MD https://t.co/0F0TdPQN2g @ivanovich13 @torresv…
eu tou com esse artigo aqui aberto no navegador desde o dia que saiu e eu nao li uma linha ainda https://t.co/vLJMSiAwab
RT @ChaturvediNeuro: New study shows that daily colchicine reduced major CV events in patients with coronary artery disease. ? potential fu…
La evidencia de un ensayo reciente ha demostrado que los efectos antiinflamatorios de la colchicina reducen el riesgo de eventos cardiovasculares en pacientes con infarto de miocardio reciente. N Engl J Med 2020; 383: 1838-1847 DOI: 10.1056 / NEJMoa2021372 https://t.co/T2RzuLupZk
RT @ChaturvediNeuro: New study shows that daily colchicine reduced major CV events in patients with coronary artery disease. ? potential fu…
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/knJB4fNaMp
Colchicine in Patients with Chronic Coronary Disease https://t.co/4ns0Yye8oZ
https://t.co/lgYmjVFsDn Colchicine in Patients with Chronic Coronary Disease LoDoCo2
RT @NEJM: Original Article: Colchicine in Patients with Chronic Coronary Disease (LoDoCo2 Trial) #ESCCongress
Colchicine in Patients with Chronic Coronary Disease | NEJM Amazing result. Much better than statins https://t.co/YjP3D4f2IN
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/lJdCQGLV2P
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/KXdTFpTITf
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/tT2eMLmieM
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @Tuhina_Neogi: Just officially published - LoDoCo2: #Colchicine in Patients with Chronic Coronary Disease. Will treatment guidelines cha…
Very interesting Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/aJgIa7yWlO
RT @Yohei_Kanzawa: ESCの頃にpublishされていた論文ですが、少量コルヒチンがこれからデフォルトになってくるのでしょうか。 慢性冠動脈疾患の患者で少量コルヒチンが心血管イベントを減少。 #CAD #コルヒチン Colchicine in Patient…
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/spFQkJIksH
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
Colchicine in Patients with Chronic Coronary Disease | NEJM Resultados a tener en cuenta https://t.co/yqrCfxGBQc
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @AbeytuaManuel: Colchicine in Patients with Chronic Coronary Disease, the risk of cardiovascular events was significantly lower among th…
RT @AbeytuaManuel: Colchicine in Patients with Chronic Coronary Disease, the risk of cardiovascular events was significantly lower among th…
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @AbeytuaManuel: Colchicine in Patients with Chronic Coronary Disease, the risk of cardiovascular events was significantly lower among th…
Colchicine in Patients with Chronic Coronary Disease, the risk of cardiovascular events was significantly lower among those who received 0.5 mg of colchicine once daily than among those who received placebo. | NEJM https://t.co/oW0UEWkpS7 https://t.co/kgjmOselAd
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/pz6AdMgFFr
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/OuyEvBeGYQ
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @FormigaFrancesc: Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/yjEp2eOMY5 @AlbertAriza3 @Medtorek @ana_apiec…
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/BuBSczsRCA
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @NEJM: Visual Abstract: Colchicine in Patients with Chronic Coronary Disease
RT @rheum_cat: @JYazdanyMD @UWRheum @r_burmester Nidorf, et al - LoDoCo2. https://t.co/Ae9G9ixSKG Colchicine in chronic CAD. Primary en…
@JYazdanyMD @UWRheum @r_burmester Nidorf, et al - LoDoCo2. https://t.co/Ae9G9ixSKG Colchicine in chronic CAD. Primary endpoint: composite of CV death, nonfatal MI, CVA Benefit with colchicine, HR 0.69 https://t.co/rnb5UkS4qF #ACR20 #ACRambassador
https://t.co/alwR038AC1
RT @pharmaciensAPES: Étude randomisée chez des patients avec maladie coronarienne chronique qui conclut que le risque d'événements cardiova…
Étude randomisée chez des patients avec maladie coronarienne chronique qui conclut que le risque d'événements cardiovasculaires est significativement plus faible chez ceux qui ont reçu 0,5 mg de colchicine par jour, par rapport ceux qui ont reçu un placebo https://t.co/D3PTS5CllO https://t.co/0eCB3AMl4l
https://t.co/eolKQWIWQa
RT @jiji_coffee: Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/F3K9DTubqV
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/F3K9DTubqV
Colchicine in Patients with Chronic Coronary Disease https://t.co/EnEO73XShR
RT @MacDeptMed: Dr. John Eikelboom (@johneikelboom) et al. conducted a randomized, controlled, double-blind trial to assess the effect of 0…
RT @vicatallah: Pacientes con enfermedad coronaria crónica mostró que ocurrencia de eventos cardiovasculares fue significativamente menor e…
RT @vicatallah: Pacientes con enfermedad coronaria crónica mostró que ocurrencia de eventos cardiovasculares fue significativamente menor e…
RT @MacDeptMed: Dr. John Eikelboom (@johneikelboom) et al. conducted a randomized, controlled, double-blind trial to assess the effect of 0…
RT @MacDeptMed: Dr. John Eikelboom (@johneikelboom) et al. conducted a randomized, controlled, double-blind trial to assess the effect of 0…
RT @MacDeptMed: Dr. John Eikelboom (@johneikelboom) et al. conducted a randomized, controlled, double-blind trial to assess the effect of 0…
RT @JulianOwenEM_CC: https://t.co/wLf8NCcEpp
https://t.co/wLf8NCcEpp
12/14 b) confirmation of previous findings in the larger LoDoCo2 trial (HR 0.69; 95% CI, 0.57 to 0.83; P<0.001) https://t.co/NEW7Q6JpQo https://t.co/BuzzjJcZkD
RT @MacDeptMed: Dr. John Eikelboom (@johneikelboom) et al. conducted a randomized, controlled, double-blind trial to assess the effect of 0…
Dr. John Eikelboom (@johneikelboom) et al. conducted a randomized, controlled, double-blind trial to assess the effect of 0.5mg of colchicine once daily in chronic coronary disease. @PHRIresearch @HEI_mcmaster @McMasterGIM https://t.co/gdtTUS2ptJ
RT @vicatallah: Pacientes con enfermedad coronaria crónica mostró que ocurrencia de eventos cardiovasculares fue significativamente menor e…
RT @vicatallah: Pacientes con enfermedad coronaria crónica mostró que ocurrencia de eventos cardiovasculares fue significativamente menor e…
RT @vicatallah: Pacientes con enfermedad coronaria crónica mostró que ocurrencia de eventos cardiovasculares fue significativamente menor e…
Pacientes con enfermedad coronaria crónica mostró que ocurrencia de eventos cardiovasculares fue significativamente menor en aquellos que recibieron colchicina en dosis bajas en comparación con placebo #VEA https://t.co/nUkSMPFbqn https://t.co/fw4gIBM1oy
【RCT】慢性冠動脈疾患患者へのコルヒチン投与は、プラセボ投与と比較して、心血管死亡、自然発生の心筋梗塞、虚血性脳卒中や虚血による冠血行再建術のリスクを減少させた。 #ペ読 https://t.co/H9CuNU39cp
Colchicine' CV benefits are mixed, and the risk of non-CV death seems greater. https://t.co/OkSkKfpvDi https://t.co/OvCg51jWDE https://t.co/3o9gTjMXsD
RT @caminalm: Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/iIam9psREA
RT @caminalm: Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/iIam9psREA
Colchicine in Patients with Chronic Coronary Disease | NEJM https://t.co/iIam9psREA